Abstract
We appreciate the comments by Dr Pisarik, because they illustrate the reason for the more in-depth analysis of blood pressure (BP) from our study published in Pediatrics .1 It is important to recognize that different statistical conclusions can result when different end points (ie, evaluation points) and statistical models are considered. The most important question, however, is how best to characterize the counterbalancing effects of sibutramine and weight loss on BP. In this study, the overall effect of sibutramine resulted in weight loss without meaningful adverse effects on BP. In our previous Annals of Internal Medicine article,2 a linear mixed-effects model for repeated measures (up to 17 visits per patient) that included baseline value as a covariate was used on change-from-baseline data to test for overall differences between treatment groups and for treatment differences at each visit. Small but statistically significant overall mean differences in systolic BP (SBP) (−0.9 mmHg [for sibutramine] vs −1.9 mmHg [for placebo]; P = .03) and diastolic BP (DBP) (+0.3 [for …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
